)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
HOOKIPA Pharma
HOOKIPA Pharma (HOOK) investor relations material
HOOKIPA Pharma has been delisted
HOOKIPA Pharma Q4 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2024 earnings summary28 Feb, 2025
Executive summary
Clinical-stage biopharma focused on arenavirus-based immunotherapeutics for oncology and infectious diseases.
2024 saw a major strategic refocus, pausing eseba-vec (HPV16+ cancer) and HB-300 (prostate cancer) programs, and prioritizing HB-700 (KRAS-mutated cancers) and Gilead-partnered HBV/HIV programs.
Significant restructuring: workforce reduced by ~80%, Vienna operations consolidated, and GMP facility project discontinued.
Financial highlights
Revenue from collaboration and licensing: $43.9M in 2024, up from $20.1M in 2023, mainly due to Roche agreement termination and milestone payments.
Net loss: $43.5M in 2024, improved from $81.6M in 2023.
Research and development expenses: $68.5M in 2024, down from $86.4M in 2023.
Cash, cash equivalents, and restricted cash: $39.9M as of Dec 31, 2024.
Accumulated deficit: $412.8M as of Dec 31, 2024.
Grant income: $7.4M in 2024, mainly from Austrian research incentives.
Outlook and guidance
Substantial doubt exists regarding ability to continue as a going concern for 12 months post-report; additional funding required.
Focus on progressing HB-700 into Phase 1 for KRAS-mutated cancers and advancing Gilead-partnered HBV/HIV programs.
Further cost-saving initiatives and potential capital raises under consideration.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from HOOKIPA Pharma
- Arenavirus immunotherapy platform advances with strong efficacy in HPV16+ and KRAS-mutant cancers.HOOK
Study Update Presentation - Clinical progress and cost cuts offset by ongoing going concern risk and cash decline.HOOKQ3 2024
- Eservivec (HB-200) shows robust efficacy in head and neck cancer, targeting approval by 2027.HOOKH.C. Wainwright 26th Annual Global Investment Conference 2024
- Positive clinical progress and restructuring amid ongoing financial risk.HOOKQ2 2024
- All proposals, including director elections and share structure changes, were approved by shareholders.HOOKAGM 2024
- HB-200 plus pembrolizumab delivers high response rates and durable outcomes in HPV16+ head and neck cancer.HOOKStatus Update
HOOKIPA Pharma
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage